Alliance for Clinical Trials in Oncology shared a post on X:
“Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer.”
Other posts about Alliance for Clinical Trials in Oncology on OncoDaily.